Press releases
2023
10 February, 2023
Half of the patients dosed in the Phase 2 AKITA study
Guard Therapeutics [GUARD] today announced that 134 of the planned 268 patients have been dosed in the global randomized, double-blinded and placebo-controlled Phase 2 clinical trial (AKITA). The AKITA study has been designed to evaluate the kidney-protective effects of the investigational drug RMC-035 in conjunction with open heart surgery...
9 January, 2023
Guard Therapeutics receives patent approval for RMC-035 in China
Guard Therapeutics today announces that the company has received a grant from the Chinese Patent Office (China National Intellectual Property Administration) for its patent application no. 201780018244.4 that protects the company's biological investigational drug RMC-035 as a product.
2022
20 December, 2022
Guard Therapeutics presents the Nomination Committee for 2023
Guard Therapeutics International AB (publ) today announces that a Nomination Committee has been appointed in accordance with previous AGM resolutions.
10 November, 2022
Guard Therapeutics has decided to carry out a directed share issue of SEK 120 million, partly subject to subsequent approval by an extraordinary general meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR...
10 November, 2022
Guard Therapeutics explores the conditions to carry out a directed share issue of approximately SEK 115 million
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) (listed on Nasdaq First North Growth Market, under the ticker GUARD) intends to explore the conditions to carry out a directed share issue of approximately SEK 115 million (the “Directed Share Issue”). The Directed Share Issue is intended to be directed...